Introduction:

Complete Omics Inc. offers cutting-edge multiomics analysis services tailored for large cohort samples, perfectly aligning with the objectives and methodologies of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) projects. Under the guidance of our Chief Scientific Officer, Dr. Hui Zhang, who not only specializes in CPTAC-related projects but is also a founding member of this crucial task, we are uniquely positioned to advance the understanding of cancer’s molecular basis through comprehensive proteogenomic analysis. Our services leverage the latest in proteomics, genomics, and metabolomics to offer unparalleled insights into cancer biology, mirroring CPTAC’s pioneering efforts in colorectal, breast, and ovarian cancer research. By integrating our analysis with the expansive CPTAC framework—which has significantly contributed to proteogenomic characterizations, open-source resources, and the acceleration of precision oncology—we facilitate the identification of proteomic-centric subtypes, the prioritization of driver mutations, and the elucidation of cancer-relevant pathways. Our commitment to supporting the APOLLO network and the International Cancer Proteogenome Consortium (ICPC) underscores our dedication to bridging oncology research with patient care and fostering international collaboration for a global impact on cancer research and therapy.

There are several milestone papers published by our founders demonstrating our expertises and impacts on large cohort clinical sample multiomics studies. Please click on the papers below:

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell. 2016 Jul 28;166(3):755-765.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019 Oct 31;179(4):964-983.e31.

Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021 Sep 16;184(19):5031-5052.e26.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and Python scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, Tissue culture cell pellets

2, Tumor tissue chunk

3, Clinical Biopsy Samples (minimal 5 mg tissue)

4, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details.

5, FFPE blocks

6, Customized sample types (please contact us to discuss)

Complete360® Enables Deep Biomarker Profiling in Groundbreaking iPSC CAR‑NK Cell Therapy Study Published in Cell

June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of…

Read more

Complete Omics Makes Landmark Debut at ASMS 2025

June 5, 2025 | BALTIMORE -Complete Omics Inc. is proud to announce a successful debut at the American Society for Mass Spectrometry (ASMS) 2025 Annual Meeting, held in Baltimore, Maryland.

Read more

Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing

Feb 20, 2025 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This…

Read more

Some of our impacts